Oxaprozin Potassium

CHEMBL1200463 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
331.4 g/mol
LogP
Phase
4

A potassium salt form of oxaprozin with the same therapeutic properties. A long-acting NSAID allowing once-daily dosing for arthritis pain and inflammation.

Molecular Weight

331.4000 g/mol

TPSA

66.20 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+]

InChI

InChI=1S/C18H15NO3.K/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14;/h1-10H,11-12H2,(H,20,21);/q;+1/p-1

Molecular Formula

C18H14KNO3

HBD / HBA

- / 4

Rotatable Bonds

5

Heavy Atoms

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A potassium salt form of oxaprozin with the same therapeutic properties. A long-acting NSAID allowing once-daily dosing for arthritis pain and inflammation.

Yes, Oxaprozin Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200463. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23694685. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.